Background: Higher risk of hepatitis B reactivation (HBV-r) has been reported in
| INTRODUCTION
Reactivation of hepatitis B virus (HBV) replication and flare up of hepatic transaminase levels have been recently reported in patients being treated with newer directly acting antiviral agents (DAAs) against hepatitis C virus (HCV). [1] [2] [3] [4] [5] [6] [7] Since definitions of HBV reactivation and other related measures (eg, clinical hepatitis) are not uniform in these reports, it is difficult to ascertain the true magnitude of the problem.
In these reports, incidence of HBV reactivation among HBsAg+ persons has ranged from 30% to 57%, while the incidence among isolated HBcAb+ is 0%-5.7%. [3] [4] [5] [6] [7] Among Veterans in the United States treated with a DAA regimen, only 9 cases of HBV reactivation were reported among 62 960 Veterans. 1 Predictors of HBV reactivation, and clinical outcomes among those with HBV reactivation are unknown. Whether HCV therapy itself increases the risk and the role of individual regimens is also unknown. We undertook this study to determine the incidence of HBV viral reactivation, serologic conversion and serum transaminase flare up among those treated with a DAA regimen compared with those treated with a pegylated interferon plus ribavirin (PEG/RBV) regimen. We further determined the incidence of hepatic decompensation and survival among those who had HBV reactivation and compared it with those who did not have HBV reactivation for the DAA and PEG/RBV treatment groups.
2 | ME TH ODS
| Data sources
We used the electronically retrieved cohort of HCV infected veterans (ERCHIVES) database for this study. ERCHIVES is a well-estab- ERCHIVES contains detailed, longitudinal demographic, clinical, laboratory, pharmacy and vital status information, and has been a source of numerous publications.
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| Study participants
For this study, all HCV infected persons with at least one positive HCV RNA who were prescribed >28 days of any of the newer DAA regimen or PEG/RBV were included. We excluded those who received both DAA and PEG/RBV regimens, whether simultaneously or sequentially, and those who were treated with first generation DAAs (boceprevir and telaprevir).
| Definitions
Treatment for HCV was defined as prescription of any new DAA or PEG/RBV regimen for >28 days. Baseline was set at the initiation of DAA or PEG/RBV therapy, and follow-up was up to the last encounter in the VA healthcare system, first hepatic decompensation date or death. HBV serologic markers (HBsAg, HBeAg, HBcAb) and HBV DNA were retrieved from routine clinical records before baseline and after initiation of treatment. Serum alanine aminotransferase (ALT) level were retrieved prior to baseline, with an average of two values closest to and before baseline used as the baseline level. All subsequent ALT values were retrieved as well. Severity of liver disease was assessed using the FIB-4 score, with cirrhosis defined as FIB-4 score >3.5 at or anytime before baseline. 15 Diabetes was defined using a previously published algorithm of blood glucose measurement, use of insulin or oral hypoglycaemic agents and ICD-9
codes. 16 Alcohol abuse and dependence were defined by presence of at least one inpatient or two outpatient ICD-9CM (International Classification of Diseases, 9th edition, Clinical Modification) codes. 
| Analyses
We determined the number and proportion of persons who experienced any of the main outcomes. We calculated the rates for HBV reactivation, seroconversion and ALT flares (per 1000 person-years of follow-up) for DAA and PEG/RBV treated groups overall. We also calculated these rates among the treatment groups by attainment of sustained virological response (SVR) and by baseline HBsAg status.
We determined the factors associated with HBV reactivation, seroconversion and ALT flares using Cox proportional hazards model.
Assumptions of proportionality were ascertained by Schoenfeld residuals, and variables not meeting the assumption were stratified.
Kaplan-Meier survival plots were constructed to show time to first hepatic decompensation event and death, for those with and without HBV reactivation.
We used SAS â (version 9.4, SAS Institute Inc., Cary, NC, USA) for analyses.
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| Regulatory approvals
The study was approved by the Institutional Review Board at VA Pittsburgh Healthcare System, Pittsburgh, PA. Appropriate approvals were also obtained from each of the databases from which data were retrieved. DAA treated persons with HBV reactivation had a shortened survival.
| RESULTS
Among
Since treatment for HCV with a DAA regimen is associated with marked reduction in liver related complications and mortality in general, 19 and the risk of HBV reactivation is relatively low (current study), the argument for treating all HCV infected persons remains strong. The survival benefit is seen early after treatment, and is apparent within the first year, underscoring the benefit of treatment. 19 We do caution the readers that the number of deaths in DAA-treated groups was very small (n = 9), and this may require further study. Declaration of funding interests: Current work was not funded specifically by any organisation. ERCHIVES was created through a 
